News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Incyte Corporation (INCY) Believes Its Experimental Meds Are Undervalued: New CEO



2/21/2014 7:26:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Incyte Corp. (INCY), the cancer-drug maker whose shares have almost tripled since August, has unrecognized value in its experimental medicines that may fuel more growth than investors expect, its new chief executive officer said. Incyte surged from about $23 as investors bought on the potential for expansion of the company’s only approved medicine, Jakafi for the bone marrow disorder myelofibrosis, CEO Hervé Hoppenot said in his first interview since taking the helm in January. There’s also excitement about another experimental drug that harnesses the immune system to fight cancer, he said.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES